(Q24250285)

1 July 2019

meta-analysis

0 references

review article

1 reference

title

Mycobacterium vaccae immunotherapy for treating tuberculosis (English)

1 reference

1 July 2019

Mycobacterium tuberculosis

main subject

1 reference

1 reference

1 reference

Mycobacterium vaccae

1 reference

2

P Garner

0 references

Guy de Bruyn

object named as

Guy de Bruyn

series ordinal

1

0 references

author name string

G de Bruyn

series ordinal

1

1 reference

PubMed ID

10796609

29 July 2017

B de

series ordinal

1

0 references

language of work or name

English

0 references

publication date

20 January 2003

1 reference

1 July 2019

Cochrane Database of Systematic Reviews

published in

1 reference

1 July 2019

volume

2003

1 reference

1 July 2019

page(s)

CD001166

1 reference

29 July 2017

1

1 reference

1 July 2019

https://api.crossref.org/works/10.1002%2F14651858.CD001166

1 reference

Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

Immunotherapy of tuberculosis with Mycobacterium vaccae NCTC 11659

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

Immunotherapy with allergens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Evaluation of HIV-1 Immunogen, an Immunologic Modifier, Administered to Patients Infected With HIV Having 300 to 549 × 10 6 /L CD4 Cell Counts A Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Allergen immunotherapy for asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

An investigation of patients with pulmonary tuberculosis in Kuwait in preparation for studies of immunotherapy with Mycobacterium vaccae.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 1. Newly-diagnosed pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Mycobacterium vaccae: a study of safety and outcome measures

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Safety and Immunogenicity of a Five-Dose Series of Inactivated Mycobacterium vaccae Vaccination for the Prevention of HIV-Associated Tuberculosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Systematic reviews in health care: Assessing the quality of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

Type 1 cytokines and the pathogenesis of tuberculosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001166

7 January 2021

10.1002/14651858.CD001166

Identifiers

DOI

1 reference

1 July 2019

PMCID

6532629

1 reference

1 July 2019

PubMed ID

10796609

1 reference